Bank of America Corp DE Reduces Stock Position in Insulet Corporation $PODD

Bank of America Corp DE lessened its holdings in Insulet Corporation (NASDAQ:PODD) by 13.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 396,040 shares of the medical instruments supplier’s stock after selling 61,769 shares during the quarter. Bank of America Corp DE’s holdings in Insulet were worth $83,105,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of PODD. State Street Corp increased its stake in shares of Insulet by 2.1% in the fourth quarter. State Street Corp now owns 3,155,489 shares of the medical instruments supplier’s stock worth $896,916,000 after acquiring an additional 65,317 shares during the period. Geode Capital Management LLC lifted its position in Insulet by 2.1% during the fourth quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier’s stock valued at $568,274,000 after purchasing an additional 41,019 shares during the period. Invesco Ltd. lifted its position in Insulet by 10.5% during the fourth quarter. Invesco Ltd. now owns 1,480,562 shares of the medical instruments supplier’s stock valued at $420,835,000 after purchasing an additional 141,167 shares during the period. Arrowstreet Capital Limited Partnership boosted its holdings in Insulet by 462.7% in the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock valued at $258,088,000 after purchasing an additional 1,011,369 shares during the last quarter. Finally, Norges Bank purchased a new stake in Insulet in the fourth quarter valued at $300,794,000.

Insulet Stock Performance

NASDAQ:PODD opened at $141.17 on Friday. The company has a market cap of $9.79 billion, a P/E ratio of 26.39, a P/E/G ratio of 1.04 and a beta of 1.10. Insulet Corporation has a twelve month low of $126.40 and a twelve month high of $354.88. The company’s 50-day moving average price is $155.42 and its 200-day moving average price is $193.60. The company has a current ratio of 2.48, a quick ratio of 1.81 and a debt-to-equity ratio of 0.65.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.19. The company had revenue of $801.70 million during the quarter, compared to analysts’ expectations of $787.39 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. Insulet’s revenue was up 23.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, sell-side analysts forecast that Insulet Corporation will post 6.51 earnings per share for the current fiscal year.

More Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet reported strong second-quarter results, with revenue of $801.7 million, up 23.5% year over year, and adjusted EPS of $1.66 versus the $1.47 consensus estimate. The results indicate continued demand for the Omnipod platform despite emerging retention issues. Insulet Corporation Q2 2026 Earnings Call Summary
• Neutral Sentiment: Several law firms are seeking lead plaintiffs for a federal securities class action covering investors who purchased PODD shares between February 21, 2025, and May 26, 2026. The lead-plaintiff deadline is August 31, 2026; the allegations have not been proven. Pomerantz class-action announcement
• Negative Sentiment: Insulet reduced its 2026 revenue outlook after identifying weaker-than-expected retention among Type 2 diabetes users. Investors are concerned that the issue could temper Omnipod adoption and second-half growth, despite management maintaining that the broader growth opportunity remains intact. Insulet cuts 2026 revenue outlook
• Negative Sentiment: Analysts sharply cut their valuations following the guidance reduction. TD Cowen lowered its price target to $144 with a hold rating, UBS reduced its target to $150 with a neutral rating, JPMorgan cut its target to $152, and Leerink downgraded PODD to market perform. Benchmark and Stifel retained buy ratings but also lowered their targets. Analysts slash Insulet forecasts
• Negative Sentiment: Investor concerns also include two recent Omnipod recalls or voluntary medical-device corrections, which have raised questions about manufacturing quality, potential regulatory scrutiny and reputational damage. The newly filed lawsuit alleges securities-law violations related to these issues and the company’s disclosures. PODD shareholder alert

Wall Street Analysts Forecast Growth

PODD has been the subject of several recent research reports. Sanford C. Bernstein reduced their price target on Insulet from $200.00 to $175.00 and set an “outperform” rating for the company in a research report on Thursday. Wells Fargo & Company lowered Insulet from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $255.00 to $144.00 in a research report on Wednesday. BTIG Research cut shares of Insulet from a “buy” rating to a “neutral” rating in a research note on Thursday. UBS Group cut their target price on shares of Insulet from $174.00 to $150.00 and set a “neutral” rating for the company in a report on Thursday. Finally, Piper Sandler cut their target price on shares of Insulet from $360.00 to $210.00 in a report on Wednesday, May 6th. Fourteen research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $195.40.

Insider Activity at Insulet

In related news, Director Timothy C. Stonesifer purchased 2,790 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was purchased at an average price of $143.51 per share, with a total value of $400,392.90. Following the completion of the acquisition, the director owned 9,041 shares in the company, valued at $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.36% of the company’s stock.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.